International phase III trial: Balixafortide (a CXCR4 antagonist) + eribulin versus eribulin alone in patients with HER2-negative, locally recurrent or metastatic breast cancer (FORTRESS) Meeting Abstract
| Authors: | Kaufman, P. A.; Martin, M.; Mayer, I.; Vahdat, L. T.; Pernas Simon, S.; Schmid, P.; McArthur, H. L.; Dent, R.; Rugo, H. S.; Barrios, C.; Bobirca, A.; Ringeisen, F.; Cortés, J. |
| Abstract Title: | International phase III trial: Balixafortide (a CXCR4 antagonist) + eribulin versus eribulin alone in patients with HER2-negative, locally recurrent or metastatic breast cancer (FORTRESS) |
| Meeting Title: | ESMO Virtual Congress 2020 |
| Journal Title: | Annals of Oncology |
| Volume: | 31 |
| Issue: | Suppl. 4 |
| Meeting Dates: | 2020 Sep 19-21/Oct 16-18 |
| Meeting Location: | Virtual |
| ISSN: | 0923-7534 |
| Publisher: | Oxford University Press |
| Date Published: | 2020-09-01 |
| Start Page: | S394 |
| End Page: | S395 |
| Language: | English |
| ACCESSION: | WOS:000573469100359 |
| DOI: | 10.1016/j.annonc.2020.08.461 |
| PROVIDER: | wos |
| Notes: | Meeting Abstract: 359TiP -- Source: Wos |
